Cervical cancer screening company TruScreen faces trading suspension for late annual report

Cervical cancer screening company TruScreen faces trading suspension for late annual report
Martin Dillon was reappointed chief executive of TruScreen in March. (Image: TruScreen)
Rebecca Stevenson
Cancer screening company TruScreen must file its late annual report by July 8 or face a trading suspension. In a notice to the New Zealand Exchange (NZX), market watchdog NZX RegCo said the firm should have filed its annual report by July 1. NZ RegCo said that because TruScreen missed that deadline, it had five business days following July 1 to publish the report to the NZX. If the report is not published, share trading for TruScreen will be suspended from the market from opening on Tuesday, July 9, until it is filed.TruScreen sh...

More Markets

Market up despite a2 demotion and Restaurant Brands bid
Markets Market Close

Market up despite a2 demotion and Restaurant Brands bid

The S&P/NZX 50 Index closed up 0.23% or 30.41 points to 13,307.40.

Jarden downgrades A2 Milk to underweight
Primary Sector

Jarden downgrades A2 Milk to underweight

Analysts nudge up their 12-month target price for A2 to $7.85 from $7.80.

Sharesies unleashes crypto coins on platform
Finance

Sharesies unleashes crypto coins on platform

The average spend during the beta launch has been about $1,000.

Comvita's survival 'uncertain' if shareholders reject takeover bid
Markets

Comvita's survival 'uncertain' if shareholders reject takeover bid

The board says there is no better offer on the table than the one from Florenz.